Yadav Chandra Shekhar, Azad Iqbal, Nasibullah Malik, Ahmad Naseem, Lohani Minaxi B, Khan Abdul Rahman
Department of Chemistry, Integral University, Lucknow, India.
Department of Laboratory Animal Facility, CSIR-CDRI, Lucknow, India.
Sci Rep. 2024 Dec 1;14(1):29838. doi: 10.1038/s41598-024-79747-8.
α,β-unsaturated carbonyl compounds have extensive applications in various fields, such as organic, inorganic, analytical, and biological. In the modern era, they offer excellent pharmacological application prospects and find widespread use in the pharmaceutical industry. The current study revealed the synthesis and characterization of a novel 3-(2-bromo-5-fluorophenyl)-1-(thiophen-2-yl) prop-2-en-1-one (CY3). In vitro their antimicrobial (Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia coli, Staphylococcus aureus, and Acinetobacter baumannii), antifungal ( Candida parapsilosis, Candida tropicalis, and Candida albicans), cytotoxicity (VERO and Hep-G2 cells), in silico, and molecular docking analysis were also performed. The in-silico analysis evaluated the drug-likeness properties of the compound CY3 using various filtering rules, including Lipinski's, Ghose filter, Veber, Egan, Muegge, and Medicinal Chemistry alerts such as Pan Assay Interference Structures (PAINS), Brenk, and Lead-likeness. Then, molecular docking studies performed using the AutoDock (AD4), Vina, and iGEMDOCK tools to determine the mechanism by which the CY3 compound interact with the bacterial strains. Here, five different receptors were selected, such as DNA gyrase, glucose 6-phosphate synthase (GlmS), dihydrofolate reductase (DHFR), dehydrosqualene synthase (DHSS), and undecaprenyl pyrophosphate synthase (UDPPS), for molecular docking analysis. The CY3 compound showed a good binding affinity with the two target proteins, DHFR and DHSS, respectively, with maximum binding energies of about - 7.07 and - 7.05 kcal/mol. The synthesized CY3 compound exhibited moderate antibacterial activity with a MIC value > 100 µg/mL against all five bacterial strains and moderate antifungal activity with a MIC value > 50 µg/mL against all three fungal strains. Drug-likeness analyses also support their favourable bioavailability.
α,β-不饱和羰基化合物在有机、无机、分析和生物等各个领域都有广泛应用。在现代,它们具有出色的药理应用前景,在制药行业中广泛使用。当前的研究揭示了一种新型的3-(2-溴-5-氟苯基)-1-(噻吩-2-基)丙-2-烯-1-酮(CY3)的合成与表征。还对其进行了体外抗菌(针对铜绿假单胞菌、肺炎克雷伯菌、大肠杆菌、金黄色葡萄球菌和鲍曼不动杆菌)、抗真菌(针对近平滑念珠菌、热带念珠菌和白色念珠菌)、细胞毒性(针对VERO和Hep-G2细胞)、计算机模拟以及分子对接分析。计算机模拟分析使用各种筛选规则评估了化合物CY3的类药性质,包括Lipinski规则、Ghose筛选器、Veber规则、Egan规则、Muegge规则以及药物化学警示,如泛测定干扰结构(PAINS)、Brenk规则和类先导物规则。然后,使用AutoDock(AD4)、Vina和iGEMDOCK工具进行分子对接研究,以确定CY3化合物与细菌菌株相互作用的机制。在此,选择了五种不同的受体,如DNA促旋酶、葡萄糖-6-磷酸合酶(GlmS)、二氢叶酸还原酶(DHFR)、脱氢鲨烯合酶(DHSS)和十一异戊烯焦磷酸合酶(UDPPS)进行分子对接分析。CY3化合物分别与两种靶蛋白DHFR和DHSS表现出良好的结合亲和力,最大结合能约为-7.07和-7.05千卡/摩尔。合成的CY3化合物对所有五种细菌菌株表现出中等抗菌活性,MIC值>100μg/mL,对所有三种真菌菌株表现出中等抗真菌活性,MIC值>50μg/mL。类药性质分析也支持它们具有良好的生物利用度。